NR4A1 and breast cancer: Adjuvant endocrine therapy (ET) is recommended to women with hormone receptor-positive (HR +) breast cancer for 5–10 years to reduce recurrence risk and mortality, but adhering to ET for this full period is challenging due to the physical and psychosocial effects of treatment.